It is expected that GYS1 ASOs have the potential to be used as an alternative treatment approach, as monotherapy in LOPD with little or no cardiac involvement, or in combination with ERT primarily for IOPD in future clinical trials for patients with Pompe disease. This evidence concerns the gene GYS1 and glycogen storage disease II.